Use of sodium meta arsenite in the manufacture of a pharmaceutical composition formulated for oral administration for the treatment of non-cancer-associated inflammation in a mammal. Use of sodium meta arsenite in a pharmaceutical composition formulated for oral administration, for the treatment of non- cancer-associated inflammation in a mammal. A kit comprising at least one therapeutically effective dosage amount of sodium meta arsenite in a composition formulated for oral administration, wherein the therapeutically effective amount of the sodium meta arsenite is sufficient to reduce or prevent inflammation in a patient.
